Core Insights - Henry Schein, Inc. (HSIC) reported third-quarter 2025 adjusted earnings per share (EPS) of $1.38, reflecting a 13.1% increase year over year and surpassing the Zacks Consensus Estimate by 8.7% [1][8] - The company achieved net sales of $3.34 billion, a 5.4% year-over-year increase, also exceeding the Zacks Consensus Estimate by 2% [2][8] - HSIC raised its full-year 2025 adjusted EPS forecast to a range of $4.88 to $4.96, up from the previous range of $4.80 to $4.94, indicating confidence in future performance [12][14] Financial Performance - Adjusted operating profit for the quarter was $266 million, down 1.1% year over year, with an adjusted operating margin of 8%, contracting by 51 basis points [9] - Gross profit totaled $1.03 billion, a 3.3% increase year over year, but gross margin contracted by 56 basis points to 30.7% due to a 6% rise in the cost of sales [7][9] Revenue Breakdown - Global Distribution and Value-Added Services segment sales rose 4.8% year over year to $2.84 billion, exceeding the forecast of $2.77 billion [3] - Global Dental Distribution merchandise sales increased by 2.9% in constant currencies, while equipment sales grew by 3.4% [4] - Global Medical Distribution sales jumped 4.6% in constant currencies, driven by strong growth in medical products and pharmaceuticals [4] Segment Performance - Global Specialty Products segment sales reached $369 million, up 5.9% on a reported basis, reflecting strong growth in dental implants and endodontics [5] - Global Technology segment sales totaled $173 million, a 9.7% increase on a reported basis, driven by cloud-based software adoption and new revenue cycle management solutions [6] Strategic Initiatives - The company successfully executed its BOLD+1 strategic plan, focusing on operational efficiency, enhancing customer experience, and expanding its digital solutions [14] - Henry Schein announced value creation initiatives expected to deliver over $200 million in operating income improvement over the next few years [13] Liquidity and Share Repurchase - At the end of Q3 2025, Henry Schein had cash and cash equivalents of $136 million, down from $145 million at the end of Q2 [10] - The company repurchased approximately 3.3 million shares at an average price of $68.62 per share, totaling around $229 million, with $980 million authorized for future repurchases [11]

Core Viewpoint - Henry Schein, Inc. (HSIC) is set to release its second-quarter 2025 results on August 5, with expectations of revenue growth but a slight decline in earnings per share (EPS) compared to the previous year [1][2]. Group 1: Earnings and Revenue Estimates - The Zacks Consensus Estimate for revenues is $3.22 billion, indicating a year-over-year increase of 2.7% [2]. - The Zacks Consensus Estimate for EPS is $1.18, reflecting a year-over-year decrease of 4.1% [2]. - Estimates for second-quarter earnings have decreased by 1 cent to $1.18 over the past 30 days [3]. Group 2: Performance Factors - The Global Distribution and Value-Added Services segment is expected to have stable conditions in U.S. and international dental merchandise and equipment markets, with potential market share gains [4]. - U.S. dental merchandise sales are anticipated to be driven by volume growth, while dental equipment sales faced challenges due to a sales deferral from the previous quarter [5]. - The U.S. medical business is likely to benefit from strong performance in the Home Solutions sector and growth from acquisitions [6]. Group 3: International Sales and New Products - International dental merchandise sales are expected to remain strong in Canada, Central Europe, and Brazil, although softness in France may offset some growth [7]. - New products introduced at the 2025 International Dental Show, such as 3D printers and intraoral scanners, may contribute positively to sales [7]. Group 4: Segment Revenue Projections - The Global Distribution and Value-Added Services segment's revenues are projected to increase by 0.3%, reaching $2.67 billion [8]. - The Global Specialty Products segment is expected to see a 2% increase in revenues, driven by TriMed and implant sales in Europe [9][11]. - The Global Technology segment is anticipated to experience a 2.4% year-over-year improvement in revenues, supported by growth in cloud-based practice management software [12].